RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
GC Biopharma Stock

GC Biopharma P/S 2024

GC Biopharma P/S

0.74

Ticker

006280.KS

ISIN

KR7006280002

As of Jul 31, 2024, GC Biopharma's P/S ratio stood at 0.74, a -17.78% change from the 0.9 P/S ratio recorded in the previous year.

The GC Biopharma P/S history

GC Biopharma Aktienanalyse

What does GC Biopharma do?

GC Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding GC Biopharma's P/S Ratio

GC Biopharma's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing GC Biopharma's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating GC Biopharma's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in GC Biopharma’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about GC Biopharma stock

What is the price-to-earnings ratio of GC Biopharma?

The price-earnings ratio of GC Biopharma is currently 0.74.

How has the price-earnings ratio of GC Biopharma changed compared to last year?

The price-to-earnings ratio of GC Biopharma has increased by -17.78% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of GC Biopharma high compared to other companies?

Yes, the price-to-earnings ratio of GC Biopharma is high compared to other companies.

How does an increase in the price-earnings ratio of GC Biopharma affect the company?

An increase in the price-earnings ratio of GC Biopharma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of GC Biopharma affect the company?

A decrease in the price-earnings ratio of GC Biopharma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of GC Biopharma?

Some factors that influence the price-earnings ratio of GC Biopharma are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does GC Biopharma pay?

Over the past 12 months, GC Biopharma paid a dividend of 1,500 KRW . This corresponds to a dividend yield of about 1.11 %. For the coming 12 months, GC Biopharma is expected to pay a dividend of 1,554.78 KRW.

What is the dividend yield of GC Biopharma?

The current dividend yield of GC Biopharma is 1.11 %.

When does GC Biopharma pay dividends?

GC Biopharma pays a quarterly dividend. This is distributed in the months of January, January, January, January.

How secure is the dividend of GC Biopharma?

GC Biopharma paid dividends every year for the past 22 years.

What is the dividend of GC Biopharma?

For the upcoming 12 months, dividends amounting to 1,554.78 KRW are expected. This corresponds to a dividend yield of 1.15 %.

In which sector is GC Biopharma located?

GC Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von GC Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GC Biopharma from 5/1/2024 amounting to 1,500 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2023.

When did GC Biopharma pay the last dividend?

The last dividend was paid out on 5/1/2024.

What was the dividend of GC Biopharma in the year 2023?

In the year 2023, GC Biopharma distributed 1,750 KRW as dividends.

In which currency does GC Biopharma pay out the dividend?

The dividends of GC Biopharma are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von GC Biopharma

Our stock analysis for GC Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GC Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.